Phase 2a Double-Blind, Randomized, Parallel Group, Dose-Ranging Study to Assess the Safety and Efficacy of Three Doses of TVGV-1 Vaccine Compared to Its Adjuvant, GPI-0100, in Subjects With Histologically Confirmed HPV Induced Cervical HSIL
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Oct 2017
At a glance
- Drugs TVGV 1 (Primary) ; GPI 0100
- Indications Cervical intraepithelial neoplasia
- Focus Adverse reactions; Therapeutic Use
- Sponsors TheVax
- 11 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 09 Sep 2016 Planned End Date changed from 1 Jun 2017 to 1 Sep 2018.
- 09 Sep 2016 Planned primary completion date changed from 1 Feb 2017 to 1 May 2018.